The purpose of this study is to compare the safety and efficacy of risankizumab to methotrexate in participants with moderate to severe plaque psoriasis.

Inclusion Criteria:

• Have a diagnosis of plaque psoriasis (with or without concurrent psoriatic arthritis) for at least 6 months before the first administration of study drug
• Have stable moderate to severe plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline Visits
• Be a candidate for systemic therapy for plaque psoriasis as assessed by the investigator
• Be a candidate for treatment with methotrexate (MTX) according to local label

Exclusion Criteria:

• Subjects with non-plaque forms of psoriasis, current drug-induced psoriasis, or active ongoing inflammatory diseases other than psoriasis that might confound study evaluations according to investigator's judgment
• Previous exposure to risankizumab
• Previous exposure to MTX
• Use of any prohibited medication or any drug considered likely to interfere with the safe conduct of the study, as assessed by the investigator
• Subject has a history of clinically significant hematologic, renal, or liver disease

AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.

Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.